FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/08/2026
Voltar para busca
Dado oficial do USPTO
SYGNATURE DISCOVERY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SYGNATURE DISCOVERY
ST13
US500000079410216Classe
1, 40, 42
Pedido
79410216
Registro
8097762
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
06/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 40, 42
Data de depósito
12/09/2024
Data de registro
13/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/01/2026
Última transação
06/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
MARSH, LAURA KATHLEEN
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Sygnature Discovery Limited
Representantes
Molly T. Eichten Larkin Hoffman Daly & Lindgren Ltd.
Classificação técnica
Classes Nice
Classe 1Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Proteins for industrial use; proteins for use in manufacture; proteins for use in scientific research; proteins for use in the manufacture of pharmaceutical products; protein in raw material form for material scienceagritechcosmeceutical research; protein in raw material form for industrial use; protein in raw material form for use in manufacture; protein in raw material form for use in scientific research; protein in raw material form for use in the manufacture of pharmaceutical products.
Classe 40
Processing of organic chemical liquids in the nature of chemical distillery services; recycling of organic solvents; purification of proteins; purification of proteins by chemical methods.
Classe 42
Scientific research and development services; drug discovery services; development of pharmaceutical preparations and medicines; drug screening for scientific research purposes; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of human and veterinary pharmaceutical drugs; research relating to medicines; services for assessing the efficacy of human and veterinary pharmaceutical drugshuman and veterinary pharmaceutical product evaluationhuman and veterinary pharmaceutical drug discovery services; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and developments; development of pharmaceutical preparations and medicines; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and drug development; research and development in the pharmaceutical and drug development fields; testing of pharmaceutical drugs; assay development services being custom design and development of biophysicalbiochemicalcell-basedphenotypicin-vitro and in-vivoassays; biological research; biological analysis; biological research laboratory services; biological researchclinical research in the field of immunotherapycancerous diseasesrespiratory diseasesneurosciencefibrotic diseasesmetabolic diseases and infectious diseases and medical research; consultancy relating to pharmacology; medical and pharmacological research services; scientific research for medical purposes in the field of immunotherapycancerous diseasesrespiratory diseasesneurosciencefibrotic diseasesmetabolic diseases and infectious diseases; research in the field of synthetic biology; research and development in the field of microorganisms and cells; chemical research and analysis services; chemical engineering; chemistry serviceslaboratory research in the field of chemistry; medicinalsyntheticanalytical and high throughput chemistry serviceshit generation and optimizationlead optimisationscale up manufacturemetaboliteanalogueimpurityanalytical standard synthesis and/or isolation and purificationstructure elucidation; clinical research in the field of immunotherapycancerous diseasesrespiratory diseasesneurosciencefibrotic diseasesmetabolic diseases and infectious diseases; organic chemistry research and analysis services; consultancy in the field of organic chemistry; laboratory research and analysis services in the field of organic chemistry; research and development services in the field of organic chemistry; developmenttesting and analysis of chemicals; developmenttesting and analysis of chemical production methods; protein and peptide mapping for scientific purposes; scientific analysis servicesscientific analysis of materials for human and veterinary pharmaceuticalmaterial scienceagritechcosmeceutical research for scientific research purposes; protein analysis services for scientific purposes; scientific research in the field of protein sequencing; protein crystallisation screening for scientific purposes; quality control for others; testing of materials; product testing; technological research in the field of immunotherapycancerous diseasesrespiratory diseasesneurosciencefibrotic diseasesmetabolic diseases and infectious diseases; industrial analysis and research services in the field of immunotherapycancerous diseasesrespiratory diseasesneurosciencefibrotic diseasesmetabolic diseases and infectious diseases; scientific services relating to cell line generation; scientific screening services being ion channel screeningiterative screeningfragment screening and in silico screeningfor scientific research purposes; compound profiling and selectivity services; X-ray and cryoelectronmicroscopy imaging and NMR structure determination of proteinsbiological macromolecules and moleculesother than for medical purposes; blood analysis services for scientific research purposes; informationadvisory and consultancy services relating to the aforesaid services.
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
18/07/2026
FIMP
FINAL DISPOSITION PROCESSED
18/07/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/05/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/04/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
20/04/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/04/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/01/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
13/01/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/11/2025
PUBO
PUBLISHED FOR OPPOSITION
25/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2025
RFNT
REFUSAL PROCESSED BY IB
09/05/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/04/2025
RFRR
REFUSAL PROCESSED BY MPU
24/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/03/2025
CNRT
NON-FINAL ACTION WRITTEN
13/03/2025
DOCK
ASSIGNED TO EXAMINER
12/03/2025
MAFR
APPLICATION FILING RECEIPT MAILED
25/11/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/11/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/11/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYGNATURE DISCOVERY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.